Literature DB >> 1636093

An eosinophil-dependent mechanism for the antitumor effect of interleukin-4.

R I Tepper1, R L Coffman, P Leder.   

Abstract

Murine interleukin-4 (IL-4) exhibits potent antitumor activity when present at the site of tumor cell challenge. Associated with tumor cell death is the appearance of an inflammatory infiltrate comprised predominantly of eosinophils and macrophages, but with few lymphocytes. Antibodies that specifically block the accumulation of granulocytes at the site of inflammation were injected in vivo to define the cell type responsible for the antitumor action of IL-4. These studies implicate eosinophils in IL-4-mediated tumor cytotoxicity. The lymphoid-independent nature of IL-4 action is supported by the analysis of mutant mouse strains with defined lymphocyte immunodeficiencies. The observed regression of established tumor masses by localized IL-4 action provides a rationale for exploring IL-4-mediated tumor killing as a potential therapy for human malignant disorders.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1636093     DOI: 10.1126/science.1636093

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  150 in total

1.  B-cell-deficient mice show an exacerbated inflammatory response in a model of Chlamydophila abortus infection.

Authors:  Antonio J Buendía; Laura Del Río; Nieves Ortega; Joaquín Sánchez; María C Gallego; María R Caro; Jose A Navarro; Francisco Cuello; Jesús Salinas
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

2.  Responsiveness of human neutrophils to interleukin-4: induction of cytoskeletal rearrangements, de novo protein synthesis and delay of apoptosis.

Authors:  D Girard; R Paquin; A D Beaulieu
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

3.  Role of polymorphonuclear neutrophils in a murine model of Chlamydia psittaci-induced abortion.

Authors:  A J Buendía; R M De Oca; J A Navarro; J Sánchez; F Cuello; J Salinas
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

4.  Pharmacologic uncoupling of angiogenesis and inflammation during initiation of pathological corneal neovascularization.

Authors:  Jeremy M Sivak; Allison C Ostriker; Amber Woolfenden; John Demirs; Rosemarie Cepeda; Debby Long; Karen Anderson; Bruce Jaffee
Journal:  J Biol Chem       Date:  2011-11-09       Impact factor: 5.157

5.  Neutrophils sustain pathogenic CD8+ T cell responses in the heart.

Authors:  Nir Grabie; Dennis T Hsieh; Chiara Buono; Jason R Westrich; Jessica A Allen; Hong Pang; George Stavrakis; Andrew H Lichtman
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

6.  Toll-like receptor 8-mediated activation of murine plasmacytoid dendritic cells by vaccinia viral DNA.

Authors:  Jennifer Martinez; Xiaopei Huang; Yiping Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-22       Impact factor: 11.205

Review 7.  Eosinophils in innate immunity: an evolving story.

Authors:  Revital Shamri; Jason J Xenakis; Lisa A Spencer
Journal:  Cell Tissue Res       Date:  2010-11-03       Impact factor: 5.249

8.  Neutrophils express oncomodulin and promote optic nerve regeneration.

Authors:  Takuji Kurimoto; Yuqin Yin; Ghaith Habboub; Hui-Ya Gilbert; Yiqing Li; Shintaro Nakao; Ali Hafezi-Moghadam; Larry I Benowitz
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

9.  Role of YopK in Yersinia pseudotuberculosis resistance against polymorphonuclear leukocyte defense.

Authors:  Sara E Thorslund; David Ermert; Anna Fahlgren; Saskia F Erttmann; Kristina Nilsson; Ava Hosseinzadeh; Constantin F Urban; Maria Fällman
Journal:  Infect Immun       Date:  2012-10-22       Impact factor: 3.441

10.  Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells.

Authors:  Rafael Carretero; Ibrahim M Sektioglu; Natalio Garbi; Oscar C Salgado; Philipp Beckhove; Günter J Hämmerling
Journal:  Nat Immunol       Date:  2015-04-27       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.